Current Report Filing (8-k)
February 07 2018 - 4:08PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
February 7, 2018
STELLAR BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified
in its charter)
British Columbia, Canada
|
|
001-37619
|
|
N/A
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
332 E. Scott Street
Port Hueneme, California 93041
(Address of principal executive offices)
(Zip Code)
(805) 488-2800
(Registrant’s telephone number, including
area code)
Not applicable.
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
þ
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
þ
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On February 7, 2018, Stellar Biotechnologies,
Inc. issued a press release announcing its financial results for its fiscal quarter ended December 31, 2017 (the Earnings Release).
The full text of the Earnings Release is attached hereto as Exhibit 99.1. The information furnished herein and therein shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities
Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Stellar Biotechnologies, Inc.
|
|
|
|
|
|
|
Date: February 7, 2018
|
By:
|
/s/ Kathi Niffenegger
|
|
Name:
|
Kathi Niffenegger
|
|
Title:
|
Chief Financial Officer
|
EXHIBIT INDEX
Stellar Biotechnologies Inc. (NASDAQ:SBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stellar Biotechnologies Inc. (NASDAQ:SBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024